This has been particularly well demonstrated in organoids derived from colorectal cancer (CRC) patients, where APC, KRAS, TP53, and SMAD4 mutations have been validated as key drivers of colorectal tumorigenesis [17,101,106,107,131]. This evidence concerns the gene KRAS and colorectal carcinoma.